

Review Article

CEREBRAL AUTOREGULATION AND CARDIOVASCULAR PHYSIOLOGY DYSFUNCTION IN TRAUMATIC BRAIN INJURY CASES: A BRIEF REVIEW

ABSTRACT

Introduction: Traumatic brain injury (TBI) is one of the leading causes of death and disability in the early years of life. Post-TBI physiological alterations vary across adult and pediatric patients and severity. This disease affects the quality of life of most people. Acute hemiparesis can cause cognitive impairments. It may also impact mood, memory, and decision-making. Furthermore, parasympathetic dysfunction and sympathetic activation appear to contribute to cardiac injury via modulation of the myocardial inflammatory response via acetylcholine receptors.

Purpose: This review aims to explain the neuronal response and cardiac dysfunction after traumatic brain injury cases.

Methods: The review used Pubmed and Google Scholar to search for articles on traumatic brain injury, neuronal response, and cardiac biomarkers. The articles were chosen for their language, publishing, content, exposure, and outcome. The main reference is obtained from up to 79 articles that meet the inclusion requirements.

Results: TBI can cause localized brain injury or diffuse brain injury from physical trauma such as diffuse axonal injury or brain edema. Repeated concussions raise the likelihood of chronic neurological, cognitive, and behavioral issues. Stress-induced catecholamine surges and inflammatory mediator production in response to trauma may also endanger cardiac disturbances. ECG changes in patients with severe traumatic brain injury are associated with cardiac dysfunction. Cardiac enzymes can be used as a diagnostic tool and indicate the patient's prognosis.

Conclusion: Cerebral autoregulation and cardiac physiological responses have a synergistic relationship in maintaining tissue homeostasis in patients with traumatic brain injury. Patients with TBI may experience cardiac dysfunction as a result of the body's exaggerated systemic response to brain injury.

Keywords: Traumatic brain injury, Cerebral autoregulation, Cardiac biomarkers, cardiac dysfunction,

1. INTRODUCTION

Traumatic brain injury (TBI) is caused by an external force on the brain, causing cognitive, physical, and psychosocial functioning problems. TBI is one of the leading causes of death and disability in the adolescent years. (1,2) TBI occurs in approximately 102 people per 100,000 in the United States each year, with 80,000 developing long-term disability. (3)

TBI is caused by motor vehicle accidents, falls, gunshot wounds, work injuries, and sports injuries. Substance addiction and alcoholism are risk factors. (3) TBI has two main mechanisms: primary and secondary injury. Primary brain injury occurs as a result of energy being transmitted to brain tissue during impact. (4) Secondary brain injury is caused by a variety of factors, including edema, ischemia, excitotoxicity, and inflammation. In response to tissue injury, a disturbance of cerebral metabolism occurs, leading to the accumulation of lactic acid due to anaerobic glycolysis, increased membrane permeability and edema formation. Excitotoxicity occurs when neurons are overstimulated with excessive amounts of neurotransmitters, especially glutamate. (5,6) Contact-type injury and intracranial haemorrhage induced by acceleration/deceleration type injury can cause localized brain damage which manifest an edema of the brain. Following the first hit, a molecular, chemical, and inflammatory cascade causes further cerebral damage. (7) There are differences between adults and children in the severity physiological alterations of many organs caused by TBI.

The diffuse injury occurs more frequently in young patients than focal injury in adults. Insensible fluid and heat loss and hypothermia will have a greater impact on youngsters than adults. In fact, post-TBI pediatric patients' CBF and volume alterations differed across young children, older children, and adults. (8) TBI also causes a systemic inflammatory response syndrome, which leads to organ system dysfunction and failure. (9) Post-TBI individuals experience physiological or anatomical changes that impact their quality of life. There are cognitive, behavioural, and hemiparetic consequences. It may also impact mood, memory, and decision-making.

GFAP, UCH-L1, S100B, and NSE are molecular biomarkers of TBI, which released by changes in physiological function of Blood-Brain Barrier (BBB). Despite several experimental research, to improve prediction power and lessen the bad outcome of TBI, clinical support of these biomarkers are still required. Interestingly, a few of these TBI biomarkers have been oxidatively changed to carbonyl groups, implying that oxidative stress markers may have predictive relevance for therapeutic strategy selection. Some medicines, such as corticosteroids and progesterone, have already been studied for TBI neuroprotection, although clinical usefulness has yet to be demonstrated in the advanced stages of the trials. In preclinical investigations, dietary antioxidants like curcumin, resveratrol, and sulforaphane have been demonstrated to reduce TBI-induced damage. As neuroprotection strategies, NRF2 are activated as antioxidant defenses caused by dietary of antioxidants which also known as carbonyl scavengers. (10)

Despite the fact that the autonomic nervous system (ANS) is a part of the central nervous system (CNS), its function after a TBI has been largely disregarded. The sympathetic and parasympathetic nerve systems make up the autonomic nervous system, and the balance between their activities determines the autonomic nervous system's impact on various organs, particularly the heart. The influence of both systems has an effect on heart rate, which is one of the end results. The time domain and frequency domain are the two basic methods for determining heart rate variability (HRV). (11)

PSH (paroxysmal sympathetic hyperactivity) can occur in TBI patients. PSH, is marked by paroxysmal tachycardia and decerebrate body posture which are stiff limbs, straight legs, and head and neck tilted back. The syndrome is linked to a worse prognosis and more extended hospital stays. (12–14) Furthermore, parasympathetic dysfunction and sympathetic activation appear to contribute to cardiac injury via modulation of the myocardial inflammatory response via acetylcholine receptors. Uncontrolled myocardial inflammation causes myocardial dysfunction and cell death. (14)

Post-TBI cardiovascular problems increase morbidity and mortality. Hypertension, hypotension, ECG alterations, cardiac arrhythmias, indicators of cardiac damage, and left ventricular failure are all possible. Because the anomalies are usually reversible, the focus should be on general supportive care and treating the underlying brain injury. cTnI elevation has been found in 20–68% of individuals. (9,15) cTnI is 100 percent sensitive and 86 percent specific for detecting LV dysfunction, compared to 29 and 100 percent for CK-MB. A high cTnI response is an independent predictor of acute regional wall motion abnormalities (WMAs) and is associated with an elevated risk of death and poor functional outcome in survivors. Decreased sensitivity of the heart to catecholamines following brain injury. Elevated BNP levels are also linked to LV dysfunction. SAH increases the risk of cardiovascular comorbidities, hospital stays, and poor outcomes or mortality linked with cardiac arrhythmias. Increased circulating cTnI is a marker of poor cardiac performance in SAH patients, including ST-segment elevation in MI, progressive myocardial hypertrophy, fibrosis, and cardiovascular mortality. (16)

The variability of TBI makes it difficult to quantify damage and predict patient fate. The variability of TBI makes it challenging to measure trauma and predict patient outcomes appropriately. Studies suggest that negative TBI outcomes (including disability, low life satisfaction, and memory loss) increase in prevalence with TBI severity. (17) This review seeks to explain cerebral autoregulation and cardiovascular dysfunction following TBI.

2. METHODS

The literature search in this review was carried out using Pubmed and Google Scholar databases with three main keywords: traumatic brain injury, neuronal response after TBI, and cardiac biomarkers in TBI cases. The articles were selected based on language, type of publication, suitability of methods, characteristics of the subject, exposure, and outcome. All references that match the inclusion criteria are processed using the Mendeley® citation manager, whereas 79 articles are obtained as the main reference.

3. RESULTS AND DISCUSSION

Traumatic brain injury (TBI) is the primary cause of disability and mortality in the United States. (6,18) In the United States, In 2019, 60,611 people died from traumatic brain injury, compared to 60,565 in 2018. (19) Dewan et al. estimated that 69 million TBIs occur annually worldwide, most of which are mild. (20) TBIs were most commonly caused by car accidents and falls, with gunshot wounds being the most lethal. Although TBI morbidity and death are high in low- and middle-income nations, new public health breakthroughs and policies appear to reduce TBI mortality effectively. (21)

TBI is classified as mild, moderate, or severe based on clinical variables such as consciousness length and severity. The Glasgow Coma Scale (GCS) can be used to stratify TBI severity after resuscitation. A GCS score of 13-15 is mild, 9-12 is moderate, and 3-8 is severe. (22,23) Symptoms range from physical to cognitive and behavioural issues. Mild TBI demands speedy recovery, whereas severe TBI necessitates an extended stay in the ICU (ICU). (17,24)

3.1 Biomechanisms of TBI

TBI can cause localized brain injury (contusion, laceration, and intracranial haemorrhage) or diffuse brain injury (accelerated/decelerated) from physical trauma (diffuse axonal injury or brain edema). TBI can be caused by impact, inertia, penetration, or blast overpressure. The force of rotation, translation, or deceleration induced by blunt trauma damages brain tissue. These forces enhanced intracranial tension by lowering the brain's latency behind the skull during rapid movement. These stress gradients cause axonal damage by stretching and shearing axons. (17,25)

Volumetric (compression/tension) and shear-type mechanical damage to brain tissue are the two types of damage. Tissue damage is predicted in terms of its location, extent, intensity, and reversibility/irreversibility. Future directions of this research are considered, including the relationship between mechanical injury and physiological brain dysfunction, as well as applicability to important medical and engineering challenges. (26) Using six post-mortem head and neck cadavers, Alshareef et al. discovered that brain movement is dependent on axial rotation, resulting in massive brain displacement. The test displaced the mid-cerebrum the most, while the cerebellum and brainstem shifted less. Greater mobility in the brain was observed with higher angular velocity and shorter pulse length. (27)

Repeated concussions increase the likelihood of chronic neurological, cognitive, and behavioural problems. Several studies examining the effects of repeated concussions in animal models using imaging or molecular methods have demonstrated significant behavioural disturbances and microglial activation after brain damage. Mild TBI in a mouse model causes short-term brain structural and histologic changes, learning and memory deficits, and impaired motor skills, which appear identical to mild TBI in humans. (28,29) Unusual neuroimaging findings can be seen in individuals and athletes with repetitive head injuries from sport-related injuries as well as adults with a history of recurrent head trauma. A retired athlete, particularly with a history of sports-related head trauma and a history of repeated concussions, reported suffering from memory, psychomotor, and cognitive problems. (30–32)

It's critical to study how physical pressures are transferred and transduced across all spatial scales of the brain in order to understand damage causes. Although the mechanical response of the brain is mostly determined by its material properties and biological structure, there are additional cellular mechanotransduction pathways. Exogenous mechanical stresses transmitted through sub-cellular components, such as extracellular matrix and cell adhesion molecules, to mechanosensitive intracellular structures that modulate mechanochemical signaling pathways can alter physiological processes.(33)

3.2 Pathophysiology and Cerebral Autoregulation of TBI

TBI causes primary and secondary brain damage. (34) Secondary brain injury occurs when numerous mechanical stresses cause brain tissue destruction, decreased cerebral blood flow, and metabolic changes. Secondary brain injury is a pathological response to an initial brain injury that includes changes in cerebral blood flow, vasospasm, BBB disruption, and edema. (35,36) The purpose of therapy and management is to prevent subsequent brain injury. TBI alters cerebral

blood flow and impairs cerebral autoregulation. (6,17,37–39) Most severe TBI patients have brain autoregulation issues. (40,41) With any changes that occur in blood pressure or metabolism, the brain will use cerebral autoregulation mechanisms to maintain oxygen and cerebral blood flow to meet the brain's needs. Autoregulation is thought to have four mechanisms. The myogenic mechanism by which changes in transmural pressure can cause vascular smooth muscle to contract. Nerve supply to cerebral blood vessels is a neurogenic mechanism. For example, activation of alpha adrenoceptors enhances inhibition of autoregulation, causing cerebral vasoconstriction. Metabolic systems can contribute to microvascular autoregulation when changes in the microenvironment, such as pCO₂ and H⁺, cause vasodilation. The endothelium also secretes vasodilators such as nitric oxide and vasoconstrictors such as endothelin-1 and thromboxane A₂, which modulate cerebrovascular tone. (42,43)

Normal cerebral blood flow is between 50 and 150 mmHg Cardiac perfusion pressure (CPP) or 60 and 160 mmHg MAP (MAP). Hypoperfusion (CBF < 15 ml/100g/min) causes cerebral ischemia. Early hyperperfusion or hyperemia in TBI patients (CBF > 55 ml/100 g/min) can worsen patient outcomes by increasing the likelihood of increased cerebral blood volume (CBV) and intracranial pressure (ICP). CBF and CPP can predict patient outcomes. Early-stage severe TBI patients with Xenon-Computed Tomography had reduced CBF. (43–47) Cerebral perfusion pressure is a stimulus that triggers an autoregulation response of the cerebrovascular system. (39)

Reduced cerebral perfusion pressure induces cerebral vein dilatation and hence increased cerebral blood volume. In general, lower cerebral perfusion pressure means lower baseline vascular pressure. Hyperperfusion above the autoregulation limit may cause hyperemia. In fact, a decline in SAP below the normal level can cause brain ischemia. (7,37) CO₂-reactivity and hyper- or hypocapnia-induced dilatation and constriction of cerebral blood vessels are needed for sufficient CBF. Vasoconstriction induces hypocarbia, decreasing CBV and CBF. Hypoventilation causes blood vessel dilation, raising CBV and ICP. (23,35,37,48) The goal of continued care is to provide the brain with the best chance of recovery possible. It's critical to keep oxygenation, normocapnia, and haemodynamic balance. Adequate sedation and analgesia alleviate pain, anxiety, and agitation while also allowing mechanical ventilation to take place. The use of multimodality brain monitoring to adapt individual patient care is beneficial. Cerebral oxygenation, CBF measurement, microdialysis, and electrophysiological monitoring are all possible options for advanced monitoring. Early nutritional supplementation is linked to improved outcomes, and enteral feeding is preferred. Hyperglycemia has been linked to subsequent ischemic damage; hence proper metabolic monitoring is critical. Continued care aims to provide the brain the best chance of recovery possible. It is critical to keep oxygenation, normocapnia, and haemodynamic balance. Adequate sedation and analgesia help minimize pain, anxiety, and agitation while also allowing mechanical ventilation to occur. (49)

Although there are changes in systemic blood pressure under normal condition, the cerebrovascular autoregulation mechanisms will maintain a steady cerebral blood flow (CBF). In the first phase, the reduced of systemic blood pressure and autoregulatory vasodilation, the CPP are initially decreased, which aims to keep CBF constant, leading to increase ICP. In the later phase, as ICP continues to rise, CPP falls below the ischemic threshold, and to reach a normal CPP, systemic blood pressure then rises. In the last phase, autoregulatory vasoconstriction occurs to stabilize the balance between systemic blood pressure and CPP. In systemic blood pressure of an injured brain, these autoregulatory mechanisms are significantly increased and often corrupted which are referred directly to the cerebral capillaries, resulting in a breakdown of the BBB, worsening cerebral edema, and increased ICP. (50) Hypocapnia and hyperventilation have been demonstrated to lower ICP and prevent hypotension in TBI patients. (41,51–53)

TBI causes massive excitatory neurotransmitter release, especially glutamate. Glutamate release in combination with a loss of ionic equilibrium can cause mitochondrial malfunction as well as other cellular problems. An acute phase of neuroexcitation, for example, has been observed in the brain shortly after impact. This occurrence has been connected to the indiscriminate release of excitatory neurotransmitters such as glutamate. Furthermore, the loss of synaptic terminals may occur as a result of the gradual degeneration connected to the energy shortage, impairing the regulation of neuronal activity patterns that are critical to brain function. As evaluated by magnetoencephalography, patients with TBI were shown to have impaired connections between brain regions, interpreting that extensive injury may play an important role in the morbidity associated with TBI. (33)

Extracellular glutamate causes overstimulation of ionotropic and metabotropic glutamate receptors with Ca⁺, Na⁺, and K⁺ movements. To compensate for the ionic pump Na⁺/K⁺-ATPase movement, cells, particularly astrocytes, engage in catabolic cycles, resulting in an unending metabolic stream that isolates cells. (7,42,54,55) Furthermore, extracellular K⁺ increases with Na⁺/K⁺-ATPase pump failure, adding to cerebral edema. (55) Edema is an increase in brain tissue fluid, including individual cells and interstitial space. Vasogenic and cytotoxic edema. Vasogenic edema occurs when liquid accumulates in the perivascular region, causing alterations in CBF and increased intracranial pressure (ICP). Particle channels activated by cytotoxic edema cause a flood of water into the intracellular space of several cell types, further disrupting the BBB. (55,56)

Accidents like a brain stroke or traumatic brain injury interrupted the Ca^{2+} homeostasis and rapidly caused neuronal death. This causes significant disturbance of Ca^{2+} homeostasis in neurons, which leads to cell damage and death. It was shown that traumatic axonal deformation causes aberrant sodium inflow via mechanically sensitive Na channels, which leads to an increase in intra-axonal Ca^{2+} via the opening of VOCCs and reversal of the $\text{Na}^+/\text{Ca}^{2+}$ exchange. Ca^{2+} enters the cell primarily through the plasma membrane through two types of Ca^{2+} channels: ionotropic receptor-operated (ligand-gated) channels (ROCs) and voltage-operated Ca^{2+} channels (VOCCs). Direct binding of particular agonists activates Ca^{2+} influx through the ionotropic ROCs. N-methyl-D-aspartate receptors (NMDARs) and some α -amino-3-hydroxy-5-methylisoxazole-4-propionate acid receptors are Ca^{2+} permeable ROCs (AMPA receptors). The physiological agonist glutamate, the central nervous system's major excitatory neurotransmitter, activates these (CNS). NMDARs provide effective Ca^{2+} entrance into neurons, so that in the CNS, NMDARs are particularly important. (57) Astrocytes are the most common cells in the brain, and they serve as a vital link between the circulatory system and neuronal upkeep. Although astrocytes are less sensitive to injury than neurons, they can both transmit and receive mechanical stresses from neurons during TBI. Astrocytes can provide damage signals to neurons via Ca^{2+} waves, send neurotransmitter signals, and change ion concentrations in the extracellular environment. The outcome of a microfluidic chamber that used a fast pressure serve to examine intracellular Ca^{2+} levels in cultured adult astrocytes show that the mechanically induced Ca^{2+} influx seen in neuron models for TBI is also present in astrocytes, and there is a viscoelastic/plastic coupling of shear stress to the Ca^{2+} influx. The Ca^{2+} influx's source is yet unclear. (58)

Because of their links to epilepsy and the role they potentially play in the construction of an integrated computational model of ion function for future research, high voltage-gated calcium ion channels are briefly reviewed here. Ca_v1 is the L-type calcium channel, Ca_v2 is the P/Q-type [$\text{Ca}_v2.1$], $\text{Ca}_v2.2$ is the R-type [$\text{Ca}_v2.2$], and $\text{Ca}_v2.3$ is the N-type [$\text{Ca}_v2.3$], and Ca_v3 is the T-type calcium channel. The genomic structure, mutation, pathophysiology, and pharmacology of these types have all been investigated. So far, the findings have been positive. The $\text{Ca}_v2.1$ P/Q type, along with the $\text{Ca}_v3.2$ T-type, has the highest association with epilepsy among the five types. They are both connected to IGE. In comparison to LVA channels, the HVA channel requires more depolarization. Despite this, both are connected to IGE, are pharmacologically sensitive, and have been shown to enhance epilepsy outcomes in patients when inhibited. The first sight of the possibility of hyperpolarized channels are provided by T-type channels and other low voltage-gated channels and negative charge transporters being connected to IGE. Congenital mutations associated to IGE have been linked to structural alterations and disease of these channels, indicating the prospect of sensitivity to more epigenetic, neuroinflammatory changes linked to more focal epilepsy such as TLE, post-traumatic epilepsy (PTE), and post-stroke epilepsy (PSE). Many polymorphisms in voltage-gated channels contribute to mutations that lead to structural and functional changes, but they do not resolve all of the issues about electrophysiologic dysfunction. (59)

Protein Kinase C (PKC) activity has been associated with neuronal death in the aftermath of TBI, and it is intimately linked to glutamate receptor signaling. $\text{PKC}\alpha$, $\text{PKC}\delta$, and $\text{PKC}\epsilon$, three essential PKC isozymes, were found largely in endothelial cells but not in astrocytes. $\text{PKC}\alpha$ and $\text{PKC}\delta$ activity can trigger NMDA receptor uncoupling from spectrin via sigma-1 receptor activation, resulting in calcium oscillations. Calcium oscillations play a role in cell death and mitochondrial malfunction. Following damage, $\text{PKC}\alpha$ and $\text{PKC}\delta$ can hyperphosphorylate structural proteins like tau and TBI61 in the hippocampus. PKC activity, interestingly, reduces cerebral edema after a TBI. (60)

3.3 Autonomic Nervous System and Cardiovascular Dysfunction

This system includes the insular and medial prefrontal cortex, cerebral amygdala, terminal stria, hypothalamus and periaqueductal grey tissue. (61,62) The amygdala is thought to modulate autonomic, endocrine, and cardiovascular responses. The autonomic nervous system is divided into two parts: sympathetic and parasympathetic (PNS). The parasympathetic nervous system (PNS) has less influence on peripheral blood vessels and is active under calmer conditions. The ANS innervates cardiac muscle, smooth muscle, and different endocrine and exocrine glands, regulating the actions of most tissues and organ systems. The ANS regulates blood pressure, digestion, bladder contraction, eye focus, and body temperature. (62)

The hypothalamic–pituitary–adrenal axis regulates stress, exercise, and metabolism. The suprachiasmatic nucleus releases C-reactive protein, which stimulates the adrenal gland to release cortisol. Stress causes an increase in a sympathetic tone which causes heart enlargement and myocardial ischemia. However, studies have indicated that cardiac abnormalities, particularly autonomic dysfunction, are related to higher mortality and morbidity in TBI. (14,50,62–64) Hypothalamic and insular cortex injuries increase the risk of cardiac issues such as blood pressure changes, arrhythmias, and myocyte death. (61,62)

In response to trauma, stress-induced catecholamine surges and inflammatory mediator production may also endanger cardiac myocytes. TBI and SAH create a systemic catecholamine “storm” that activates the adrenal glands and increases sympathetic outflow. (9,61) Following a TBI, neurogenic variables such as increased catecholamine release and

inflammation may cause systemic issues. (65) As a whole, brain damage can cause systemic abnormalities such as increased sympathetic activity and immune system depression causing hypertension, tachycardia, arrhythmia, and an increase in oxygen demand, which can lead to subendocardial ischemia and ventricular dysfunction. This is due to unopposed peripheral vasodilation and heart failure. Regular vasopressor/inotropic medication usually lowers arterial pressure. Norepinephrine is routinely used after a TBI to regulate arterial pressure and CPP reliably. (61,66) Patient with TBI with previous systolic dysfunction is problematic because it may lead to secondary brain injuries, as adequate cardiac output is critical in maintaining CBF after injury. Poor outcomes are also seen in patient with early hypotension and hypertension after TBI. A research by Krishnamoorthy et al. find that in 7 people (22%) of 32 patients developed systolic dysfunction after TBI. Compared to patients who did not develop systolic dysfunction ($P < 0.01$ for all comparison) that 7 patient who developed systolic dysfunction experienced early elevation of mean arterial pressure (MAP), systolic blood pressure (SBP), and heart rate. (67)

3.4 Paroxysmal sympathetic hyperactivity

TBI, stroke, anoxic brain injury, tumors, infections, spinal injuries, and serotonin syndrome are all examples of PSH. The prevalence of PSH ranges from 8–to 33 percent, with TBI accounting for 79.4 percent of cases. PSH affects 15 – 33 % percent of moderate to severe TBI patients. (68) After TBI, PSH has been described as being associated with hyperthermia, tachycardia, hypertension, diaphoresis, tachypnea, dystonia (hypertonia or spasticity), and even motor features such as extensor/flexion posturing. (69) The dominant theory suggests that the damage of central autonomic network such as insular cortex, amygdala, hypothalamus, medulla, periaqueductal gray matter, parabrachial complex, and nucleus of the hypothalamus can lead to PSH. In fact, the pathophysiology of PSH is still unknown. (68)

There is no widely effective treatment algorithm for PSH. Treatment aims to reduce associated adverse effect such as cardiac hypertrophy, muscle wasting, dehydration, contractures, and delayed recovery, contributing to increased morbidity. Multiple medications are frequently required to control the various symptoms. Bromocriptine, a dopaminergic agent, has been shown to reduce body temperature and sweating. Clonidine and other alpha agonists reduce heart rate and blood pressure. (70) Beta-blockers protect the heart by lowering heart rate, perfusion volume, and mean arterial pressure. This effect reduces myocardial oxygen consumption, preventing a heart attack. Beta-blockers also have a neuroprotective effect by lowering CBF, lowering cerebral consumption of oxygen and glucose as metabolism slows. (69)

3.5 Electrocardiographic (ECG) Abnormalities

Electrocardiographic (ECG) changes, including morphological changes and rhythm disturbances, are common in TBI. Several studies have shown that ECG changes in patients with severe traumatic brain injury are associated with cardiac dysfunction and increased hospital mortality. (50,64,71) The most common ECG changes in patients with SAH and intracerebral hemorrhage (ICH) are repolarization abnormalities such as QT interval prolongation and morphology changes in ST-segment and T wave. ST-segment changes, flat or inverted T waves, prominent U waves, and QTc interval prolongation (QTc is the QT interval corrected for heart rate) are the most common findings. (9,72) Prolonged QT repolarization abnormalities and morphological late repolarization abnormalities (MERA), but not ischemic-like ECG changes, are associated with cardiac dysfunction after isolated TBI. (50) A study of 198 adult patients admitted to the ICU with TBI showed ECG abnormalities consisting of impaired ventricular repolarization, conduction disturbances, QTc prolongation and arrhythmias. Arrhythmias are found more frequently in patients with diffuse brain injury. Even so, abnormalities on the ECG cannot pinpoint the location of the lesion in the brain. (71) A 12-lead ECG may be a helpful screening tool for isolated TBI patients with heart abnormalities prior to additional diagnostic investigations or therapies. The severity of brain injury, malignant cerebral edema, and extracranial disease, especially cardiac electrical dysfunction, are all associated with TBI-related mortality. Through central autonomic dysfunction with higher catecholamine levels, shifts in the potassium to sodium ion ratio, and the inflammatory response associated with brain injury, cardiovascular damage resulting from a brain injury can lead to sudden cardiac death. Consequently, cardiovascular injury associated with brain injury, manifesting as aberrant electrocardiogram (ECG) readings, can have a significant impact on the outcome of TBI patients. (73)

3.6 Cardiac Biomarkers in TBI

TBI has a progressive pathology: alterations occur over time and follow the initial trauma. An objective indicator of normal biological processes, pathogenic processes, or response to exposure or intervention (including therapeutic intervention) is a biomarker. (74) To diagnose myocardial damage and LV dysfunction, cardiac troponin I (cTnI) is preferred over CK-MB. CK-MB can elevate due to skeletal muscle injury, renal failure, intramuscular injection, intense activity, and exposure to toxins and drugs. (75) A study exploring changes in CSF CK and CK-MB levels in TBI mortality revealed an increase in CSF CK and CK-MB after TBI. CSF CK-BB is also useful for clinically estimating the degree of brain damage and can be used to assess neurologic prognosis. (76) High troponin levels have been identified in traumatic and nontraumatic brain

injuries. Acute myocardial injury produces serum cardiac troponins, which are solely produced by wounded myocardial cells. According to a pooled research, Higher cTn is strongly related to a high death rate in patients with TBI. (77) Myocytes produce BNP (B-type natriuretic peptide) and are elevated in conditions of heart disease, sepsis, stroke, TBI, and blood-brain barrier disorders. Elevated serum BNP is associated with LV dysfunction. (9,78) According to another study by Turner et al. (2013), biomarkers could one day be used to identify chronic traumatic encephalopathy (CTE). Additionally, using a biomarker, it may be feasible to follow illness severity and progression (s). A prospective CTE biomarker should be non-invasive, diagnostic, and linked to disease severity, allowing healthcare practitioners to follow the illness's progression. It should be sensitive enough to identify the condition and allow for a diagnosis when used in conjunction with clinical evidence of CTE symptoms and a history of recurrent head trauma. As previously stated, there is currently no approved way of detecting CTE prior to post-mortem pathological investigation. An easily available biomarker with the aforementioned qualities would provide clinicians with a valuable tool for diagnosing and tracking CTE patients. There is currently little research targeted at identifying a biomarker(s) specific for CTE. Numerous study have been conducted in order to determine biomarkers for TBI and other varieties of neurotrauma. One of the most challenging aspects of looking for a CTE biomarker is that the symptoms of CTE might be confused with those of a range of other neurologic illnesses. Conducting human clinical investigations in the search for acceptable biomarkers may become more complicated as a result of this. On the other hand, the neuropathology of CTE is not dissimilar to that of other neurodegenerative illnesses, as hyperphosphorylated tau and TDP-43 deposition are detected in a range of neurodegenerative diseases. (79)

4. CONCLUSION

Cerebral autoregulation and cardiac physiological responses have a synergistic relationship in maintaining tissue homeostasis in patients with traumatic brain injury. Patients with TBI may experience cardiac dysfunction as a result of the body's exaggerated systemic response to brain injury. The use of ECG and cardiac biomarkers can help establish the diagnosis and indicate the prognosis of patients with suspected cardiac dysfunction. However, more research is needed to look at changes in cardiac enzyme levels and their correlation with the overall outcome of TBI.

COMPETING INTERESTS DISCLAIMER:

The Authors declare that they have no conflict of interest.

REFERENCES

1. Agustia N, Utami GT, Nauli FA. Gambaran Kualitas Hidup Pasien Pasca Mengalami Cedera Kepala: Literature Review. *Jkep*. 2021;6(2):146–58.
2. Irdesel J, Aydiner SB, Akgöz S. Rehabilitation outcome after traumatic brain injury. *Neurocirugia*. 2007;18(1):5–15.
3. Bushnik T, Hanks RA, Kreutzer J, Rosenthal M. Etiology of traumatic brain injury: Characterization of differential outcomes up to 1 year postinjury. *Archives of Physical Medicine and Rehabilitation*. 2003 Feb 1;84(2):255–62.
4. Bellander BM, Olafsson IH, Ghatan PH, Bro Skejo HP, Hansson LO, Wanecek M, et al. Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. *Acta Neurochirurgica* [Internet]. 2011 Jan [cited 2022 May 26];153(1):90. Available from: /pmc/articles/PMC3015189/
5. Hinson HE, Rowell S, Schreiber M. Clinical evidence of inflammation driving secondary brain injury: A systematic review. *J Trauma Acute Care Surg* [Internet]. 2015 Jan 13 [cited 2022 May 26];78(1):191. Available from: /pmc/articles/PMC4297199/
6. Ng SY, Lee AYW. Traumatic Brain Injuries: Pathophysiology and Potential Therapeutic Targets. Vol. 13, *Frontiers in Cellular Neuroscience*. Frontiers Media S.A.; 2019.
7. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Vol. 99, *British Journal of Anaesthesia*. Oxford University Press; 2007. p. 4–9.
8. Figaji AA. Anatomical and Physiological Differences between Children and Adults Relevant to Traumatic Brain Injury and the Implications for Clinical Assessment and Care. *Frontiers in Neurology* [Internet]. 2017 Dec 14 [cited 2022 May 9];8(DEC). Available from: /pmc/articles/PMC5735372/
9. Gregory T, Smith M. Cardiovascular complications of brain injury. *Continuing Education in Anaesthesia, Critical Care and Pain* [Internet]. 2012;12(2):67–71. Available from: <http://dx.doi.org/10.1093/bjaceaccp/mkr058>
10. Mendes Arent A, Souza LF de, Walz R, Dafre AL. Perspectives on molecular biomarkers of oxidative stress and antioxidant strategies in traumatic brain injury. *Biomed Res Int* [Internet]. 2014 [cited 2022 May 26];2014. Available from: <https://pubmed.ncbi.nlm.nih.gov/24689052/>

11. Keren O, Yupatov S, Radai MM, Elad-Yarum R, Faraggi D, Abboud S, et al. Heart rate variability (HRV) of patients with traumatic brain injury (TBI) during the post-insult sub-acute period. *Brain Inj* [Internet]. 2005 Aug 10 [cited 2022 May 26];19(8):605–11. Available from: <https://pubmed.ncbi.nlm.nih.gov/16175814/>
12. Siponkoski ST, Wilson L, Steinbüchel N von, Sarajuuri J, Koskinen S. Quality of life after traumatic brain injury: Finnish experience of the QOLIBRI in residential rehabilitation. *J Rehabil Med* [Internet]. 2013 [cited 2022 May 9];45(8):835–42. Available from: <https://pubmed.ncbi.nlm.nih.gov/24002322/>
13. Khalid F, Yang GL, McGuire JL, Robson MJ, Foreman B, Ngwenya LB, et al. Autonomic dysfunction following traumatic brain injury: Translational insights. *Neurosurgical Focus*. 2019;47(5).
14. Hilz MJ, Liu M, Roy S, Wang R. Autonomic dysfunction in the neurological intensive care unit. *Clin Auton Res* [Internet]. 2019 Jun 1 [cited 2022 May 9];29(3):301–11. Available from: <https://pubmed.ncbi.nlm.nih.gov/30022321/>
15. Caro DHJ. The Yin and Yang of Integrated Care: Systemic Imperatives for Traumatic Brain Injuries. *The Open Public Health Journal*. 2014;7:6–11.
16. Chen Z, Venkat P, Seyfried D, Chopp M, Yan T, Chen J. Brain-Heart Interaction: Cardiac Complications after Stroke. Vol. 121, *Circulation Research*. Lippincott Williams and Wilkins; 2017. p. 451–68.
17. Blennow K, Brody DL, Kochanek PM, Levin H, McKee A, Ribbers GM, et al. Traumatic brain injuries. *Nature Reviews Disease Primers*. 2016 Nov 17;2.
18. Galgano M, Toshkezi G, Qiu X, Russell T, Chin L, Zhao LR. Traumatic Brain Injury: Current Treatment Strategies and Future Endeavors. *Cell Transplantation* [Internet]. 2017;26(7):1118–30. Available from: <https://us.sagepub.com/en-us/nam/open-access-at-sage>
19. Centers for Disease Control and Prevention. Surveillance Report of Traumatic Brain Injury-related Deaths by Age Group, Sex, and Mechanism of Injury—United States, 2018 and 2019. 2022.
20. Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, et al. Estimating the global incidence of traumatic brain injury. *J Neurosurg* [Internet]. 2019;130:1080–97. Available from: <https://thejns.org/doi/abs/10.3171/2017.10.JNS17352>
21. Khellaf A, Danyal -, Khan Z, Helmy A. Recent advances in traumatic brain injury. *Journal of Neurology* [Internet]. 2019;266:2878–89. Available from: <https://doi.org/10.1007/s00415-019-09541-4>
22. Vella MA, Crandall M, Patel MB. Acute Management of Traumatic Brain Injury. *Surg Clin North Am*. 2017;97(5):1015–30.
23. Chung P, Khan F. Traumatic Brain Injury (TBI): Overview of Diagnosis and Treatment. *Journal of Neurology & Neurophysiology*. 2013;05(01).
24. Kowalski RG, Flora :, Hammond M, Weintraub AH, Nakase-Richardson R, Zafonte RD, et al. Recovery of Consciousness and Functional Outcome in Moderate and Severe Traumatic Brain Injury Supplemental content. *JAMA Neurol* [Internet]. 2021;78(5):548–57. Available from: <https://jamanetwork.com/>
25. Stemper BD, Pintar FA. Biomechanics of concussion. Vol. 28, *Progress in Neurological Surgery*. S. Karger AG; 2014. p. 14–27.
26. el Sayed T, Mota A, Fraternali F, Ortiz M. Biomechanics of traumatic brain injury. *Computer Methods in Applied Mechanics and Engineering*. 2008 Oct 15;197(51–52):4692–701.
27. Alshareef A, Giudice JS, Forman J, Shedd DF, Reynier KA, Wu T, et al. Biomechanics of the Human Brain during Dynamic Rotation of the Head. *J Neurotrauma*. 2020;37(13):1546–55.
28. Yang Z, Wang P, Morgan D, Bruijnzeel AW, Lin D, Pan J, et al. Temporal MRI characterization, neurobiochemical and neurobehavioral changes in a mouse repetitive concussive head injury model. *Scientific Reports* [Internet]. 2015 Sep 1;5(1):11178. Available from: <http://www.nature.com/articles/srep11178>
29. Robinson S, Berglass JB, Denson JL, Berkner J, Anstine C v, Winer JL, et al. Microstructural and Microglial Changes After Repetitive Mild Traumatic Brain Injury in Mice. *J Neurosci Res*. 2017;95(4):1025–35.
30. Cunningham J, Broglio SP, O'grady M, Wilson F. History of Sport-Related Concussion and Long-Term Clinical Cognitive Health Outcomes in Retired Athletes: A Systematic Review. *Journal of Athletic Training* [Internet]. 2020;55(2):132–58. Available from: <http://dx.doi.org/10.4085/1062-6050-297-18.S1>
31. Diaz-Arrastia R, Gugger J, Lippa S, Wojtowicz M, Victoria Echlin H, Rahimi A. Systematic Review of the Long-Term Neuroimaging Correlates of Mild Traumatic Brain Injury and Repetitive Head Injuries. *Frontiers in Neurology* | www.frontiersin.org [Internet]. 2021;1:726425. Available from: www.frontiersin.org
32. McKee AC, Cantu RC, Nowinski CJ, Tessa Hedley-Whyte E, Gavett BE, Budson AE, et al. Chronic Traumatic Encephalopathy in Athletes: Progressive Tauopathy After Repetitive Head Injury. *J Neuropathol Exp Neurol* [Internet]. 2009;68(7):709–35. Available from: <https://academic.oup.com/jnen/article/68/7/709/2917002>
33. Hemphill MA, Dauth S, Yu CJ, Dabiri BE, Parker KK. Traumatic Brain Injury and the Neuronal Microenvironment: A Potential Role for Neuropathological Mechanotransduction. *Neuron*. 2015 Mar 18;85(6):1177–92.
34. Capizzi A, Woo J, Verduzco-Gutierrez M. Traumatic Brain Injury: An Overview of Epidemiology, Pathophysiology, and Medical Management. Vol. 104, *Medical Clinics of North America*. W.B. Saunders; 2020. p. 213–38.
35. Claassen JAHR, Thijssen DHJ, Panerai RB, Faraci FM. Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation. *Physiol Rev* [Internet]. 2021 Oct 1 [cited 2022 Apr 26];101(4):1487–559. Available from: <https://pubmed.ncbi.nlm.nih.gov/33769101/>

36. Riera JJ, Parthasarathy AB, Zheng Y, Duffin J, Sobczyk O, McKetton L, et al. Cerebrovascular Resistance: The Basis of Cerebrovascular Reactivity. *Front Neurosci* [Internet]. 2018;12:409. Available from: www.frontiersin.org
37. Kinoshita K. Traumatic brain injury: Pathophysiology for neurocritical care. Vol. 4, *Journal of Intensive Care*. BioMed Central Ltd.; 2016.
38. Algattas H, Huang JH. Traumatic Brain Injury pathophysiology and treatments: Early, intermediate, and late phases post-injury. Vol. 15, *International Journal of Molecular Sciences*. MDPI; 2014. p. 309–41.
39. Sheriff FG, Hinson HE. Pathophysiology and Clinical Management of Moderate and Severe Traumatic Brain Injury in the ICU. *Semin Neurol*. 2015;35(1):42–9.
40. Gunge Riberholt C, Damkjaer Olesen N, Thing M, Bogh Juhl C, Mehlsen J, Hvass Petersen T. Impaired Cerebral Autoregulation during Head Up Tilt in Patients with Severe Brain Injury. *PLoS One* [Internet]. 2016;11(5). Available from: www.glostruphospital.dk
41. Zeiler FA, Mathieu F, Monteiro M, Glocker B, Ercole A, Beqiri E, et al. Diffuse Intracranial Injury Patterns Are Associated with Impaired Cerebrovascular Reactivity in Adult Traumatic Brain Injury: A CENTER-TBI Validation Study. *Journal of Neurotrauma* [Internet]. 2020 [cited 2022 Apr 26];37(14):1597. Available from: [/pmc/articles/PMC7336886/](https://pubmed.ncbi.nlm.nih.gov/3236886/)
42. Rivera-Lara L, Zorilla-Vaca A, Geocadin RG, Healy RJ, Ziai W, Mirski MA. Cerebral Autoregulation-oriented Therapy at the Bedside. *Anesthesiology* [Internet]. 2017;126(6):1187–99. Available from: http://pubs.asahq.org/anesthesiology/article-pdf/126/6/1187/519196/20170600_0-00032.pdf
43. Armstead WM. Cerebral Blood Flow Autoregulation and Dysautoregulation. *Anesthesiol Clin*. 2016;34(3):465–77.
44. Honda M, Ichibayashi R, Yokomuro H, Yoshihara K, Masuda H, Haga D, et al. Early Cerebral Circulation Disturbance in Patients Suffering from Severe Traumatic Brain Injury (TBI): A Xenon CT and Perfusion CT Study. *Neurol Med Chir*. 2016;56:501–9.
45. Inoue Y, Shiozaki T, Tasaki O, Hayakata T, Ikegawa H, Yoshiya K, et al. Changes in Cerebral Blood Flow from the Acute to the Chronic Phase of Severe Head Injury. *JOURNAL OF NEUROTRAUMA*. 2005;22(12):1411–8.
46. Lassen NA, Christensen MS. Physiology of Cerebral Blood Flow. *Br J Anaesth*. 1976;48:719.
47. ter Laan M, van Dijk JMC, Elting JWJ, Staal MJ, Absalom AR. Sympathetic regulation of cerebral blood flow in humans: A review. Vol. 111, *British Journal of Anaesthesia*. Oxford University Press; 2013. p. 361–7.
48. Salehi A, Zhang JH, Obenaus A. Response of the cerebral vasculature following traumatic brain injury. *Journal of Cerebral Blood Flow & Metabolism*. 2017;37(7):2320–39.
49. Dinsmore J. Traumatic brain injury: An evidence-based review of management. *Continuing Education in Anaesthesia, Critical Care and Pain*. 2013;13(6):189–95.
50. Krishnamoorthy V, Prathep S, Sharma D, Gibbons E, Vavilala MS. Association between electrocardiographic findings and cardiac dysfunction in adult isolated traumatic brain injury. *Indian Journal of Critical Care Medicine* [Internet]. 2014;18(9):570–4. Available from: www.ijccm.org
51. Rangel-Castilla L, Lara LR, Gopinath S, Swank PR, Valadka A, Robertson C. Cerebral Hemodynamic Effects of Acute Hyperoxia and Hyperventilation after Severe Traumatic Brain Injury. *Journal of Neurotrauma*. 2010;27:1853–63.
52. Puppo C, Kasproicz M, Steiner LA, Yelicich B, Afrodite Lalou D, Smielewski P, et al. Hypocapnia after traumatic brain injury: how does it affect the time constant of the cerebral circulation? *Journal of Clinical Monitoring and Computing* [Internet]. 2020;34:461–8. Available from: <https://doi.org/10.1007/s10877-019-00331-x>
53. Beqiri E, Czosnyka M, Lalou AD, Zeiler FA, Fedriga M, Steiner LA, et al. Influence of mild-moderate hypocapnia on intracranial pressure slow waves activity in TBI. *Acta Neurochirurgia* [Internet]. 2020;162:345–56. Available from: <https://doi.org/10.1007/s00701-019-04118-6>
54. Jamjoom AAB, Rhodes J, Andrews PJD, Grant SGN. The synapse in traumatic brain injury. *Brain*. 2021;144(1):18–31.
55. Jha RM, Kochanek PM, Simard JM. Pathophysiology and treatment of cerebral edema in traumatic brain injury. Vol. 145, *Neuropharmacology*. Elsevier Ltd; 2019. p. 230–46.
56. Cash A, Theus MH. Mechanisms of Blood-Brain Barrier Dysfunction in Traumatic Brain Injury. *IntJ MolSci* [Internet]. 2020;21(9):3344. Available from: www.mdpi.com/journal/ijms
57. Wojda U, Salinska E, Kuznicki J. Calcium ions in neuronal degeneration. *IUBMB Life* [Internet]. 2008 [cited 2022 May 27];60(9):575–90. Available from: <https://pubmed.ncbi.nlm.nih.gov/18478527/>
58. Maneshi MM, Sachs F, Hua SZ. A Threshold Shear Force for Calcium Influx in an Astrocyte Model of Traumatic Brain Injury. *J Neurotrauma* [Internet]. 2015;32:1020–9. Available from: www.liebertpub.com/neu
59. Sizemore G, Lucke-Wold B, Rosen C, W. Simpkins J, Bhatia S, Sun D. Temporal Lobe Epilepsy, Stroke, and Traumatic Brain Injury: Mechanisms of Hyperpolarized, Depolarized, and Flow-Through Ion Channels Utilized as Tri-Coordinate Biomarkers of Electrophysiologic Dysfunction. *OBM Neurobiol* [Internet]. 2018 Jun 1 [cited 2022 May 26];2(2):1–1. Available from: <https://pubmed.ncbi.nlm.nih.gov/29951646/>
60. Lucke-Wold BP, Logsdon AF, Smith KE, Turner RC, Alkon DL, Tan Z, et al. Bryostatin-1 Restores Blood Brain Barrier Integrity following Blast-Induced Traumatic Brain Injury. *Mol Neurobiol* [Internet]. 2015 Dec 1 [cited 2022 May 26];52(3):1119–34. Available from: <https://pubmed.ncbi.nlm.nih.gov/25301233/>

61. Padilla-Zambrano HS, García-Ballestas E. "Broken Heart Syndrome" Cardiovascular Manifestations of Traumatic Brain Injury. *Heart Mind* [Internet]. 2018;2(1):12–5. Available from: <http://www.heartmindjournal.org>
62. Esterov D, Greenwald BD. Autonomic dysfunction after mild traumatic brain injury. *Brain Sciences*. 2017 Apr;7(8).
63. Chaikittisilpa N, Krishnamoorthy V, Lele A v, Qiu Q, Vavilala MS. Characterizing the Relationship between Systemic Inflammatory Response Syndrome and Early Cardiac Dysfunction in Traumatic Brain Injury HHS Public Access. *J Neurosci Res*. 2018;96(4):661–70.
64. Prathep S, Sharma D, Hallman M, Joffe A, Krishnamoorthy V, MacKensen GB, et al. Preliminary Report on Cardiac Dysfunction after Isolated Traumatic Brain Injury. *Crit Care Med* [Internet]. 2014 Jan [cited 2022 May 21];42(1):142–7. Available from: </pmc/articles/PMC3841242/>
65. Andersson EE, Bedics BK, Falkmer T. Mild Traumatic Brain Injuries: A 10-Year Follow-Up. *J Rehabil Med*. 2011;43:323–9.
66. Gutierrez-Orozco F, Chitchumroonchokchai C, Lesinski GB, Suksamrarn S, Failla ML. α -Mangostin: Anti-Inflammatory Activity and Metabolism by Human Cells. *J Agric Food Chem* [Internet]. 2013 Apr 24 [cited 2022 May 9];61(16):3891. Available from: </pmc/articles/PMC3793015/>
67. Krishnamoorthy V, Rowhani-Rahbar A, Chaikittisilpa N, Gibbons • Edward F, Frederick •, Rivara P, et al. Association of Early Hemodynamic Profile and the Development of Systolic Dysfunction Following Traumatic Brain Injury. *Neurocrit Care*. 2017;26:379–87.
68. Nguembu S, Meloni M, Eve Endalle G, Dokponou H, Dada OE, Senyuy WP, et al. Paroxysmal Sympathetic Hyperactivity in Moderate-to-Severe Traumatic Brain Injury and the Role of Beta-Blockers: A Scoping Review. *Emergency Medicine International* [Internet]. 2021;2021. Available from: <https://doi.org/10.1155/2021/5589239>
69. Wang F, Kodali M, Upadhy D, Zhang GM, Zheng RZ, Lei ZQ, et al. Identification and Management of Paroxysmal Sympathetic Hyperactivity After Traumatic Brain Injury. *Frontiers in Neurology* | www.frontiersin.org [Internet]. 2020;11:81. Available from: www.frontiersin.org
70. Stecker M, Meyer KS. Understanding paroxysmal sympathetic hyperactivity after traumatic brain injury. *Surg Neurol Int* [Internet]. 2014;5:S490–2. Available from: <http://www.surgicalneurologyint.com>
71. Lenstra JJ, Kuznecova-Keppel Hesselink L, la Bastide-van Gemert S, Jacobs B, Nijsten MWN, van der Horst ICC, et al. The Association of Early Electrocardiographic Abnormalities With Brain Injury Severity and Outcome in Severe Traumatic Brain Injury. *Frontiers in Neurology* [Internet]. 2021 Jan 8 [cited 2022 May 21];11:597737. Available from: </pmc/articles/PMC7819976/>
72. Masoud Hashemian A, Ahmadi K, Taherinia A, Davood Sharifi M, Ramezani J, Behzad Jazayeri S, et al. ECG changes of cardiac origin in elderly patients with traumatic brain injury. *Med J Islam Repub Iran* [Internet]. 2015;29:306. Available from: <http://mjiri.iums.ac.ir>
73. Lee JH, Lee DH, Lee BK, Cho YS, Kim DK, Jung YH. Role of electrocardiogram findings in predicting 48-h mortality in patients with traumatic brain injury. *BMC Neurology* 2022 22:1 [Internet]. 2022 May 24 [cited 2022 May 26];22(1):1–9. Available from: <https://bmcnneurol.biomedcentral.com/articles/10.1186/s12883-022-02717-y>
74. Davanzo JR, Sieg EP, Timmons SD. Management of Traumatic Brain Injury. Vol. 97, *Surgical Clinics of North America*. W.B. Saunders; 2017. p. 1237–53.
75. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. *CMAJ* [Internet]. 2005 Nov 8 [cited 2022 May 21];173(10):1191–202. Available from: <https://pubmed.ncbi.nlm.nih.gov/16275971/>
76. Zwirner J, Anders S, Bohnert S, Burkhardt R, da Broi U, Hammer N, et al. Screening for Fatal Traumatic Brain Injuries in Cerebrospinal Fluid Using Blood-Validated CK and CK-MB Immunoassays. *Biomolecules* [Internet]. 2021;11:1061. Available from: <https://doi.org/10.3390/biom11071061>
77. El-Menyar A, Sathian B, Wahlen BM, Al-Thani H. Serum cardiac troponins as prognostic markers in patients with traumatic and non-traumatic brain injuries: A meta-analysis. *Am J Emerg Med* [Internet]. 2019 Jan 1 [cited 2022 May 21];37(1):133–42. Available from: <https://pubmed.ncbi.nlm.nih.gov/30318278/>
78. El-Menyar A, Goyal A, Latifi R, Al-Thani H, Frishman W. Brain-Heart Interactions in Traumatic Brain Injury. Vol. 25, *Cardiology in Review*. Lippincott Williams and Wilkins; 2017. p. 279–88.
79. Turner RC, Lucke-Wold BP, Robson MJ, Omalu BI, Petraglia AL, Bailes JE. Repetitive traumatic brain injury and development of chronic traumatic encephalopathy: a potential role for biomarkers in diagnosis, prognosis, and treatment? *Front Neurol* [Internet]. 2013 [cited 2022 May 26];3(186). Available from: <https://pubmed.ncbi.nlm.nih.gov/23335911/>